ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
Drug: folic acid
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer|
|United States, Texas|
|For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.|
|San Antonio, Texas, United States|